Dr Alfons Nonell-Canals
Founder and Chief Executive Officer (CEO)
Nonell-Canals is a specialist in Computer-Aided Drug Design, in the development of such software, and in large-scale
chemical and biological analyses. He holds a bachelor's degree in
Pharmacy from the University of Barcelona and PhD in Computational
Chemistry from Rovira i Virgili University. After some
post-doc sessions in the Pompeu Fabra University and the Hospital del Mar Medical Research Institute, he decided to establish Mind the Byte to achieve
the synergy with his experience and modern AI and cloud computing
techniques. He is a member of the CataloniaBio
committee and sits on the board of directors of Bioinformatics
Irene Espelta Figuerola
Project Management Director
She has a bachelor's degree in Biochemistry and Molecular Biology by the University Rovira i Virgili and MSc in Nutrition and Metabolism by University Rovira i Virgili/University of Barcelona. She did a specific postgraduate training in european-funded projects in the Ramon Llull University (La Salle). She has worked as Project Manager at Anaxomics Biotech, to then move to lead the Project Management Department for a year at Mind the Byte, where she managed all kind of public/private funded projects. Furthermore, she used to collaborate with the Catalan Associaciation of Biotechnologists
as treasurer and supporting some scientific workshops organization.
Dr Anna Ferrer Admetlla
Business Development Director
She holds a bachelors degree in Biothecnology from the Autonomous University of Barcelona. She received her PhD from the Pompeu Fabra University and did a postdoc with Prof Nielsen at UC-Berkeley, where she developed statistical methods. After her post-doc at UC-Berkeley, she was hired as senior research scientist at Switzerland, where she held a joint appointment with Prof D Wegmann at the University of Fribourg and Prof JD Jensen at the École Polytechnique Fédérale de Lausanne. During her double appointment, she developed a HMM-based approach to infer selection and demography from time-series samples. She applied this numerical approach on multi-time point case-control experimental data to understand the effects of an antiviral drug in-vitro.
Dr Jordi Lanuza Masdeu
Director of Communications
He has a scientific background with a degree in
Biotechnology from the Autonomous University of Barcelona and an
MSc in Biomedicine from the University of Barcelona. He pursued his
PhD at the Institute for Research in Biomedicine (IRB Barcelona) working
on cell-signalling pathways in the context of type 2 diabetes. After
finishing the PhD, he changed fields and studied an MSc in Scientific
Communication at the Pompeu Fabra University. Simultaneously, he
started working at the Office of Communications of the IRR Barcelona as a
Public Engagement Officer. Afterwards, he
moved to the United Kingdom employed as a Strategic Network Coordinator
at the University of Cambridge. He combined this position with being an External Referee Selector
for the UK Medical Research Council. He returned to Barcelona to
launch the Communications Department of the Institute of Evolutionary
Biology, position after which he started at the current role in Mind the
Dr Thomas Högberg
Chief Strategy Officer (CSO)
He has spent over 45 years in the pharmaceutical industry with experience from big pharma (Astra, AstraZeneca), mid pharma (ALK-Abello, LEO Pharma) and biotech (7TM Pharma) where he headed various departments (medicinal chemistry, chemical research, DMPK, Patent, Project and Portfolio Management). He has had leading roles from early drug discovery to marketed products and worked in several therapeutic areas including dermatology, metabolic diseases, inflammatory diseases, respiratory diseases, CNS diseases, and infection. He has also been engaged in business development and due diligence in in-and outlicensing in several companies. Dr Högberg earned a PhD in Organic Chemistry from Uppsala University (Sweden) and is Assoc Prof at the KTH Royal Institute of Technology in Stockholm and Fellow of the Royal Society of Chemistry (CChem, FRSC). In the scientific arena, he has published over 100 papers and book chapters and is the co-inventor on over 50 patent applications.
Dr Melchor Sanchez Martinez
He holds a bachelor's degree in Biotechnology from the University of Vic, a MSc in Biophysics from the University of Barcelona and a MSc in Theoretical and Computational Chemistry from the Rovira i Virgili University. He received his PhD from the University of Barcelona, working on Theoretical and Computational Chemistry mainly focused on computational biochemistry and biophysics. After finishing the PhD, he joined Mind the Byte where he is in charge of carrying out client consultancy and I+D projects (internally and externally funded). Additionally, he is also course instructor at the Open University of Catalonia, where he assesses students of the MSc in Bioinformatics and Bioestatistics.
Dr David Vidal
He received his Ph.D. in Organic Chemistry from the University of Barcelona in 2006. Under the supervision of Prof. Miquel Pons, he specialized in the design and development of modeling techniques and algorithms for drug discovery. In 2007, after a postdoctoral stage at Origenis GmbH (Munich, Germany), he returned to Barcelona to join the scientific team of Chemotargets where, in the course of nine years, he contributed to the development of their discovery platform and, in collaboration with different pharmaceutical and biotechnology companies, participated in different drug discovery projects mainly focused on the early identification and optimization of new molecular entities. At the end of 2016, he joined Mind the Byte as Head of In Silico Pharmacology being appointed R&D director in 2017, with the global objective of designing, developing and consolidating company's drug discovery SaaS platform aimed at the modeling and simulation of preclinical and clinical data.